SUMMER Trial: Mesh Versus Suture Repair in Small Umbilical Hernias in Adults: a Study Protocol for a Prospective Randomized Double-blind Multicenter Clinical Trial

Maria Melkemichel (maria.melkemichel@ki.se)
Karolinska Institute Department of Clinical Sciences Danderyd Hospital: Karolinska Institutet Institutionen for kliniska vetenskaper Danderyds sjukhus. Department of Surgery, Södertälje Hospital, Södertälje  https://orcid.org/0000-0002-2161-2888

Sven Bringman
Department of clinical science and education, Södersjukhuset,Karolinska Institutet, Stockholm, Sweden. Department of Surgery, Södertälje Hospital, Södertälje.

Gabriel Granåsen
Department of public health and clinical medicine, Umeå university, Umeå.

Björn Widhe
Karolinska Institute Department of Clinical Sciences Danderyd Hospital: Karolinska Institutet Institutionen for kliniska vetenskaper Danderyds sjukhus. Department of Surgery, Södertälje Hospital, Södertälje

Research Article

Keywords: Small umbilical hernia, mesh repair, suture repair, recurrence, randomized clinical trial

DOI: https://doi.org/10.21203/rs.3.rs-475715/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: Small umbilical hernia repair is one of the most common surgical performance in general surgery. Yet, a gold standard procedure for the repair is still lacking today. There is an increasing evidence that mesh could be advantageous compared to suture repair in lowering recurrence rates. An additional important question remains with regard to optimal anatomical positioning of the mesh. We hypothesize that the use of an onlay mesh in small umbilical hernia defects can reduce recurrence rates without increasing complications compared to a simple suture repair.

Methods: A prospective, national, multicenter, randomized, double-blind clinical trial comparing a standardized 4x4 cm onlay mesh to a conventional suture repair will be conducted. 288 patients with a primary elective umbilical hernia £ 2 cm from 7 participating Swedish surgical centers will be enrolled. Intraoperative randomization will take place using a centralized web-based system resulting in total allocation concealment. Stratification will be done by surgical site and by defect size. Trial participants and follow-up clinical surgeons will be blinded to the assigned allocation. The primary outcome assessed will be postoperative recurrence at 1 and 3 years. Secondary outcomes assessed will be postoperative complications at 30 days and pain 1 year after surgery.

Discussion: Currently, there has been no randomized clinical trial comparing recurrence rates between an onlay mesh repair and a simple suture repair for small umbilical hernia defects. How to best repair a small umbilical hernia continues to be debated. This trial design should allow for a good assessment of differences in recurrence rate with due to the large sample size and the adequate follow-up. Surgeons’ concerns surrounding optimal anatomical positioning and fear for larger required dissections are understandable. A small onlay mesh may become an easy and a safe method of choice to reduce recurrence rates. Guidelines for small umbilical hernia repairs have stressed the need for reliable data to improve treatment recommendations. We can expect that this trial will have a direct implication on small umbilical hernia repair standards.

Trial registration: ClinicalTrials.gov Identifier: NCT04231071. Registered on 31 January 2020. SUMMER Trial underwent external peer review as part of the funding process.

Introduction

Background and rationale (6a)

A small umbilical hernia repair in adults is one of the most common general surgical performance in Sweden [1]. Yet, there is still no gold standard procedure. Traditionally, these small hernia defects have been repaired with an open suture repair, using either a Mayo's suture or a simple suture technique [2]. Mesh repairs have been primarily reserved more for larger umbilical hernia defects. However, similar results demonstrating lower recurrence when using mesh to repair groin and incisional hernias have also been observed for small umbilical hernia repairs [3].
All data from previous studies has demonstrated lower recurrence rates using mesh reinforcement in open repairs of small umbilical hernias [4–11]. These limited retrospective hand-full published studies, reported recurrence rates for suture repair of 4–15 % compared to much lower rates for mesh repair of 0–5 %. However, only two of them are randomized clinical trials, whereas one of them consisted of only 50 patients with a follow up of 22 months [6]. The other trial was dated 2001 of included hernias both over and under 3 cm with different mesh positioning [11]. Similar results have been published in a Danish nationwide register-based study, which collected data pertaining to 4,786 umbilical and epigastric hernia repairs ≤ 2 cm from the Danish Ventral Hernia Database [12]. The reoperation rate for recurrence in the cohort was 2.2 % for mesh repair and 5.6 % for suture repair. The same authors also investigated the total clinical true recurrence rates, which were surprisingly high at 21 % for suture repair and 10 % for mesh repair [13]. This confirms that reoperation for recurrence really underestimates the true recurrence rates and the need for further clinical trials.

Recently, in 2018, a large, randomized, double-blind, controlled trial with 300 participants was published, comparing suture to mesh repair in umbilical hernias of 1–4 cm [14]. The trial demonstrated that mesh reinforcement had a significant reducing effect on recurrence compared to only a suture repair. Still, the preperitoneal mesh positioning examined in this trial could be difficult to implement in a safe way without enlarging the defect in the case of small umbilical hernias. Also, the role of mesh in very small umbilical hernias < 1 cm remains uncertain. The latter is discussed in a recent meta-analysis [15], together with the important debated question regarding optimal placement of the mesh in these small umbilical hernia defects; sublay or onlay? Additionally, Köckerling et al, newly concluded in a registry-based study of small umbilical hernia repairs < 2 cm which included over 30,000 repairs, that suture repair was associated with an increased risk of recurrence [16].

Despite the above-mentioned advantages with mesh reinforcement, surgeons have certainly still remained reluctant to use mesh in small ventral hernias. A possible explanation could be due to open questions surrounding optimal anatomical positioning and concerns about larger required dissections and the associated increase in risk of complications. A meta-analysis found an increased risk for seroma in the mesh group (7.7 %) compared to the suture repair group (3.8 %) [17]. In contrast, another meta-analysis showed a clear benefit of mesh repair in reducing recurrence rates without any difference in complication rates between mesh and suture repair [18]. The presence of seroma could seem to be slightly too high in the meta-analysis and the explanation could be that the analyzed studies are heterogeneous to hernia size and to other factors as mesh positioning. For example, the risk of developing a seroma is theoretically higher in larger hernias repaired with a retro-muscular technique, rather than in very small defects, repaired with a small onlay mesh.

As in groin hernia repair, chronic pain has also become an important issue to assess in umbilical hernia repair. It has mainly been investigated in retrospective studies, demonstrating an incidence of chronic pain of 4–20% without no differences attributable to different surgical techniques [19, 20]. In the Danish cohort-study the chronic pain rate was low and similar in small umbilical and epigastric hernias, regardless of whether a mesh or a suture repair was performed [13].
Although many studies argue that mesh reinforcement offers an advantage also in small umbilical hernias to lower the risk of recurrence, the suitable anatomical mesh position for repairing small umbilical hernias is still uncertain. There are currently no randomized clinical trials comparing a simple suture repair to a simple suture repair coupled with a small onlay mesh for small umbilical hernia defects. Guidelines for small umbilical hernia repairs have stressed the need for reliable data to improve treatment recommendations [21]. We can expect that this trial will provide valuable knowledge and have a direct effect on small umbilical hernia repair standards. If results prove superiority in lowering recurrence rates by using an onlay mesh repair without any significant increase in the occurrence of surgical site complications between the study groups, mesh will have to be considered in treatment standards for small umbilical hernia defects. A small onlay mesh repair could become a safe and easy method of choice.

**Objectives {7}**

The aim of this trial is to compare recurrence rates 1 year and 3 years after surgery between a simple suture repair to a simple suture repair with a small onlay mesh in elective primary umbilical hernias ≤ 2 cm. We hypothesize that by using a small onlay mesh in the repair of these small umbilical hernia defects, the occurrence of recurrence rates will significantly be reduced (superiority) without it causing a higher surgical site complication rates at 30 days or pain rates at 1 year (non-inferiority) compared to a simple suture repair.

**Trial design {8}**

The SUMMER (Suture Umbilical Mesh Repair) Trial is the first Swedish national, prospective, parallel group, superiority, randomized, double-blind, controlled, multicenter trial with patients undergoing open repair for small elective primary umbilical hernias ≤ 2 cm. A web-based online central randomization method with a 1:1 ratio for the two study groups will be applied. The randomization will be performed intraoperatively following the measurement of the defect; the small umbilical hernia defect will be closed with either a simple primary suture repair or with an attached small, flat only mesh on the sutured defect. Trial participants and follow-up clinical surgeons will be blinded to the assigned allocation. Participants will be visiting the outpatient clinical at 30 days, 1 year and 3 years after surgery for the assessment of the outcomes. Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) are presented in Figure 1.

**Methods: Participants, Interventions And Outcomes**

**Study setting {9}**

Participating units are currently 7 surgical departments in Sweden with a special interest in hernia repair, with Södertälje Hospital leading the trial. Co-sites are; The surgical department at Danderyds Hospital,
Norrtälje Hospital, Enköping Hospital, Sophiahemmet/GHP, Mora Hospital and Frölunda Hospital. Depending of the rate of inclusion, additional centers may be included in the trial.

**Eligibility criteria {10}**

288 adults (> 18 years) will be included in the trial. Patients are recruited to participate in the study by the surgeon during the clinical outpatient meeting if there is an indication requiring surgery. If patients meet all the inclusion criteria and none of the exclusion criteria, they will be invited to take part in the study. All potential trial participants are provided with oral and written information and need to provide written informed consent during the inclusion in the trial prior to randomization and surgery. An umbilical hernia in this trial is defined according to the European Hernia Society definition as a primary midline abdominal wall defect from 3 cm above to 3 cm below the umbilical [22]. This definition has been commonly used in previous studies, which allows comparison of results with earlier and future publications on this type of hernia. Inclusion and exclusion criteria are presented in Table 1.

**Who will take informed consent? {26a}**

The surgeon at the outpatient clinical setting will obtain informed consent from the potential trial participants after the surgeon has ensured that the potential participants has read and understood written information about the trial. The written information will be sent to the potential participants in advance. The surgeon will check that the potential participants has understood parts concerning benefits and risks of participation and will also ensure that the potential participants accept that the treatment will be allocated at random with blinding at the follow-up time.

**Additional consent provisions for collection and use of participant data and biological specimens {26b}**

No additional consents provisions are asked from the potential participants except for being part of the SUMMER Trial protocol.

**Interventions**

**Explanation for the choice of comparators {6b}**

There is an increasing evidence that mesh reinforcement, compared to a simple suture repair, could be advantageous to lower the high recurrence rates also in smaller umbilical hernias. However, an important question remains as to what the optimal anatomical position to place the mesh is. The investigators hypothesize that the use of *an onlay mesh* in small umbilical hernia defects can reduce recurrence rates without increasing postoperative complications compared to a simple suture repair.

**Intervention description {11a}**

At study initiation, all surgeons participating in the study that will include and operate on patients will be given an oral presentation on the trial and the online electronic data capture software REDCap. The surgeons will receive a demonstration of the surgical technique by the principal investigators to ensure
that they all use the same standardized techniques for the suture repair and the mesh repair described in the protocol. The operation is performed under general anesthesia. No antibiotics are given in any group. Mayo's hernioplasty of the defect will not be allowed in this trial.

In the controlled sutured group, the surgeon will perform an open incision in the umbilical area followed by dissection of the hernia sac (Figure 2a). The largest hernia defect diameter will be measured with a ruler and patients will then be randomized intra-operatively to either suture or mesh repair. The surgeon will then perform a suture repair with a continuous non-absorbable monofilament suture 2/0 of the aponeurosis defect. The defect will be sutured in the transversal direction, beginning with a start-knot and ending with a stop-knot (Figure 2b).

In the intervention onlay mesh group, the operation will be performed initially as above. The subcutaneous tissue will then be dissected from the aponeurosis so that the surgeon can apply a 4x4 cm Ultrapro Advanced™ (© 2018 Ethicon Inc, part of the Johnson and Johnson family of companys, Germany) mesh to the site of the defect that has been closed. The mesh will be fixated with single non-absorbable monofilament suture 2/0; first one in the center of the mesh and then one in each corner in a transversal direction to prevent the risk of nerve-entrapment. In total, 5 single sutures will attach the mesh (Figure 2c). Ultrapro Advanced™ is a lightweight composite polypropylene mesh with an absorbable monofilament poliglecarpone-25 component. The weight is 71 g/m² at implantation and ~39 g/m² after absorption. The shrinking of the mesh is ~5 %.

If the surgeon creates an opening in the umbilical skin during the procedure, the patient will be excluded from the study. In both study groups, an absorbable monofilament suture 3/0 or 4/0 will be used to affix the umbilical skin to the aponeurosis. Closure of the skin will be done with the same type of suture with an intra-cutaneous running suture (Figure 2d). Finally, the same type and size of the bandage will be placed on the wound.

Criteria for discontinuing or modifying allocated interventions (11b)

There are no criteria for discontinuing or modifying allocated interventions. Participants may choose to stop being part of the trial whenever they want to without any reason. Withdrawal of informed consent before the operation will not affect the patient's entitlement to receive treatment. The surgeon and the patient will then together consider what treatment will be provided for the small umbilical hernia. Usually, suture repair is still the standard care.

Strategies to improve adherence to interventions (11c)

None, as the trial participant will have already been operated on and given an intervention that cannot be changed.

Relevant concomitant care permitted or prohibited during the trial (11d)

No special provisions.
Provisions for post-trial care {30}

None, beyond standard care of patients in Sweden. Participants will be treated the same as any other patients in the healthcare system. The trial participants will have benefit of the Swedish national patient insurance system that compensates for any harm that may arise in the trial.

Outcomes {12}

The primary outcome assessed will be whether a small onlay mesh in the repair of primary umbilical hernias ≤ 2 cm reduces the risk of recurrence compared to a simple suture repair 1 year and 3 years after surgery. Patients will be investigated for recurrence at an outpatient clinical exam via a physical examination of the abdomen by the investigating surgeon following a standard medical assessment. If there is an uncertainty of a recurrence, a computed tomography (CT) scan of the abdomen with a valsalva maneuver will be performed.

Secondary outcomes assessed will be to compare the two groups of patients with regard to surgical postoperative complications and pain. The postoperative complication rate at 30 days after surgery will be investigated for the presence of a seroma, haematoma or a wound infection. A seroma is defined as an accumulation of clear fluid in the surgical field. A haematoma is defined as an accumulation of blood in the wound area. An infection is defined as a surgical site infection (SSI). The postoperative complication will be graded according to the Clavien-Dindo classification [23]. Grade ≥ 1 is defined as a presence of a postoperative complication. These findings will be investigated clinically with a physical examination by the investigating surgeon following an ordinary medical assessment. If there is an uncertainty of a postoperative complication, a CT scan of the abdomen will be performed. The intensity of postoperative local pain will be assessed with the VAS scale at 30 days. The postoperative pain rate 1 year after surgery will be assessed by the Ventral Hernia Pain Questionnaire (VHPQ). This questionnaire is considered to be a reliable and validated tool to assess pain after ventral hernia surgery [24].

Participant timeline {13}

Participant timeline is presented in Figure 1.

Sample size {14}

Taking previous report’s recurrence rates into consideration; we have predicted and assumed a 12 % recurrence rate in the suture group and 3 % in the mesh group. In order to detect a difference in recurrence rate of 9 percentage points after 3 years, a sample size of 288 (144/group,) will be required to achieve a power of 80% at a significance level of α= 0.05, allowing for a dropout frequency of 10%.

Recruitment {15}

Umbilical hernias are very common in the outpatient clinical settings and therefore we have confidence in achieving the required number of participants. Despite the COVID-19 pandemic, we have already
managed to include 115 trial participants within a 12 months period of unregular healthcare. At each surgical center a devoted site investigator will identify potential trial participants from the submitted referrals to the site before the outpatient clinical. Written information about of the trial will be sent out in advance to the potential participants. The site investigator will also continue to motivate the site to recruit the expected number of patients.

**Assignment of interventions: allocation**

**Sequence generation (16a)**

The randomization will take place intra-operatively in each hospital, after the inclusion of the patient, by the operating surgeon, directly following the measurement of the hernia defect. If the hernia defect is \( \leq 2 \) cm, the patient has met all of the inclusion criteria’s and none of the exclusion criteria’s, the patient will be randomized during surgery to one of the two operation techniques. Patients will be allocated within the software, using computer-based pre-generated randomization lists. The randomization will be conducted using a block randomization with a 1:1 relationship between the two procedures, stratified by surgical site and defect size (\( \leq 10 \) mm and >10 mm).

**Concealment mechanism (16b)**

Randomization will utilize a web-based central randomization system. All random sequences were checked for correctness prior recruitment. Total concealment of the allocation will be achieved by 4 or 6 block random sequence generation.

**Implementation (16c)**

The biostatistician has generated the allocation sequence. The surgeons will enroll participants to the trial and also assign the participants to interventions by randomizing participants intraoperatively through the online electronic data capture software REDCap.

**Assignment of interventions: Blinding**

**Who will be blinded (17a)**

Both participants and outcome assessment surgeons will be blinded to the assigned allocation at each of the following follow-ups. The operating surgeon, who is unblinded, will not perform the follow-up visits. The operating surgeon will record in the patient’s hospital health journal that the procedure that has been done according to the SUMMER Trial without specifying if a suture repair or a suture repair with an onlay mesh has been performed. The repair that was performed is then registered in REDCap intra-operatively. This information in REDCap will be locked and hidden for the follow-up clinical investigator. The surgeon will also record the allocated intervention in a separate paper document (not attached to the participant’s hospital health record), which the secretary will keep securely in a separate folder.

**Procedure for unblinding if needed (17b)**
Unblinding is only approved in the case of recurrence or a serious postoperative surgical site infection to allow for an adequate re-operation. At this point, the outcome for this patient has been reached. Unblinding will also be allowed if informed consent is withdrawn. If necessary, there are several procedures for revealing a participant's allocated intervention in this trial. The allocated intervention can be found in REDCap, but only by the principal investigators. Also, the folded separate paper document folder at each site can be obtained by the secretary.

Data collection and management

Plans for assessment and collection of outcomes {18a}

Demographics and comorbidities of the trial participants will be collected at baseline by the surgeon at the outpatient visit prior to surgery and allocation. Assessment of the outcomes after surgery will be blinded to the allocation and procedures are described in detail under section 12. Data collection of the outcomes will be completed by a surgeon at the 30-days, 1-years and 3-years outpatient follow-up visits. At each visit, a palpable physical examination of the trial participant’s abdomen will be performed by the investigating surgeon following a standard medical assessment and the outcome will be registered in REDCap. The Ventral Hernia Pain Questionnaire will be completed at the 1-year visit to assess pain. The schedule of enrolment, interventions and assessments is provided in Figure 1.

Plans to promote participant retention and complete follow-up {18b}

None, beyond normal encouragement to visit the outpatient clinic for the follow-ups and motivate the trial participants that the trials results can really benefit umbilical hernia patients in the future.

Data management {19}

When participants are included in the trial by the surgeon, after oral and written consent, baseline data will be entered into REDCap by the surgeon. All trial participants will be given a trial number which will be used on all Case Report Forms for that participant within the framework of REDCap during the randomization and the follow-up registration. Only people involved in the trial and authorized by the principal investigators will have access to REDCap and to randomize during surgery via username and passwords specific to each surgical center. Each surgical center will only have data available in REDCap for the participants included at its center and will not have an ability to influence or change any of the data.

Confidentiality {27}

Only the above authors will have access to all patient-identifying data, ensuring data protection and preventing unauthorized transportation of data. All person-related data is kept strictly confidential and will be handled in accordance with European general data protection regulations during and after the trial has ended.
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}

None

Statistical methods

Statistical methods for primary and secondary outcomes {20a}

All analysis will be performed and data will primarily be presented for the intention to treat study population. Corresponding per-protocol analysis will also be performed and results from this analysis will be attached as a supplement in the final publication. Statistical tests for the primary endpoint will be two-sided using a significance level of $\alpha = 0.05$. The primary endpoint will be the recurrence rate observed during a follow-up period of 1 and 3 years and will be analyzed using a mixed logistic regression model with dummy variables specifying each time of follow-up. The primary analysis will be adjusted for fixed effects: defect size and body mass index with a random intercept for each site. Both adjusted and unadjusted results will be presented. Reciprocal Kaplan-Meier curves will be generated to illustrate time to recurrence. Statistical tests for the secondary endpoints will be one-sided using a significance level of $\alpha = 0.05$. Secondary outcomes that will be analyzed by comparing the treatment groups are postoperative complications 30 days after surgery (Clavien-Dindo scale) and postoperative pain 1 year after surgery (assessed with Ventral Hernia Pain Questionnaire). Postoperative complications and postoperative pain will be analyzed using ordinal logistic regression. Presence of postoperative complications will be analyzed using binary logistic regression. Secondary analyses will be adjusted for fixed effects: defect size and body mass index with a random intercept for each site.

Interim analyses {21b}

There will be no planned interim analyses.

Methods for additional analyses (e.g. subgroup analyses) {20b}

At this time there are no planned additional subgroup analyses. However, if this is reconsidered during the trial it will be stated in the statistical analysis prior to data lock.

Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}

A comparison of possible discrepancies between the results of the intention to treat analysis and per-protocol analysis will be included as part of a sensitivity analysis. In case of a dropout of more than 10% at the 1-year and 3-year follow up, a sensitivity analysis will be made by comparing the results from the patient’s recorded outcomes at follow up with a corresponding analysis made by using multiple imputation.

Plans to give access to the full protocol, participant level-data and statistical code {31c}
This manuscript is the full protocol. Anyone interested in other participant level-data or statistical code can contact the corresponding author. The uncoded data and statistical code will be uploaded to the ELN system - the secure electronic database of research notebooks, logbooks and research documentation maintained by Karolinska Institutet.

Oversight and monitoring

Composition of the coordinating centre and trial steering committee {5d}

At each participating surgical center, a responsible surgeon performing the site investigator role, will ensure and agree to lead the SUMMER Trial in accordance with the terms of the trial’s clinical study protocol, ethical standards of national research, the latest version of Helsinki declaration and the Good Clinical Practice guidelines. The site investigator at each surgical center will motivate others at the site to recruit the expected number of patients, assist with all trial related questions and ensure that the surgeons at the site are collecting and reporting high quality data while protecting the participant’s personal data. Monthly reports will be given to the principal investigators who will give the trial up-dates every three months.

Composition of the data monitoring committee, its role and reporting structure {21a}

In this trial a data monitoring committee is considered not to be needed, since the entire trial can be adequately monitored by the online electronic data capture software REDCap. The site investigators at each surgical center will oversee the trial safety and monitor trial progress with regard to recruitment and follow-up. The principal investigators will have a regular contact with each site investigator to ensure that the SUMMER Trial is led in accordance with the trial’s clinical study protocol.

Adverse event reporting and harms {22}

The SUMMER Trial involves treatments which are well established in the clinical practice for individuals requiring umbilical hernia repair. All early complications in relation to the surgical procedures will be documented and registered within 30 days. Participants will be requested to only contact the surgical unit if a postoperative complication is noted before the 30-day visit. The site investigator at the surgical center will be instructed to report to the principal investigator if an alarming accumulation of postoperative complications is noted. The principal investigator will in that case assess with an uninvolved surgeon whether the trial has to be stopped prematurely.

Frequency and plans for auditing trial conduct {23}

The principal investigators will have a regular contact with each site investigator to ensure enrollment, recruitment, correct data entry, randomization by REDCap and that the follow-ups are in accordance with the SUMMER Trial protocol.
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) \{25\}

All protocol modifications prior to inclusion or follow-up will be notified to the ethical committee and approval of a new protocol version will be required prior to inclusion or follow-up of the trial participants. The protocol amendments will be communicated to relevant parties such as trial participants, site investigators, trial surgical center’s and ClinicalTrial.gov.

Dissemination plans \{31a\}

The trial results will be presented in both national and international conferences and published in a peer-review journals. The investigators will also discuss trial results with healthcare professionals within the research area and relevant patient groups that can benefit from the results.

Discussion

This large, national, multicenter trial is aiming to answer the question whether small umbilical hernia repairs can benefit from using a small onlay mesh to lower the recurrence rates compared to only a simple suture repair. Up until now, the benefits of mesh in these small umbilical hernia repairs have been debated, with evidence that is based on a few small, heterogeneous clinical trials. To our knowledge, this is the only registered trial comparing the onlay mesh method to a simple suture repair. We know from clinical experience that surgeons, despite new data supporting the advantages of mesh, may still be reluctant to use mesh for small hernia defects. A possible explanation could be due to complicated optimal mesh positioning considerations and perceived increase in the risk of complications. Therefore, if successful, this trial may offer surgeons conclusive evidence that a small onlay mesh repair can be easy, safe and superior to a simple suture method of repairing small umbilical hernia defects.

The trial population was chosen to be representative of the broader patient population. All patients with an umbilical hernia, despite the initial described size, are evaluated for eligibility to be enrolled in the study at the participating surgical centers. The specific aim is to investigate the treatment for small umbilical hernias $\leq 2$ cm specifically, since the mid-sized hernias ($2$–$4$ cm) are presumed to already be performed with a mesh reinforcement anyway as part of standard treatment protocols. The exclusion criteria were set up to give adequate balance between the randomized groups and to only investigate primary elective umbilical hernias. Patients with rare co-morbidities that can affect the outcomes or risk becoming overweight in one study group will be excluded.

The outcomes measured in this trial reflects the concerning issues in using an onlay mesh in umbilical hernia repairs: recurrence, pain and surgical site postoperative complications. The trial design will allow for good detection of differences in recurrence rate due to the large sample size and sufficient long-term results extending to 3 years. For the secondary outcomes assessment, the 30-day postoperative complications will be investigated in accordance with an international system for grading complications. Furthermore, a validated pain questionnaire for ventral hernia repairs was chosen to assess pain 1 year
after surgery. Other questionnaires were considered for use in this trial but were not chosen due to the increased efforts required to conduct the trial at several different surgical centers. The multi-center design reduces distortions related to individual surgeons’ experience and any surgical center bias. The results can therefore be expected to be generalized and applicable for other routine clinical settings. Neither do we expect a learning curve issue to be associated with the onlay mesh method. The technique is not a new one and the method will have been demonstrated to all participating surgeons. We except that the method is easy to adapted and perform.

The use of the online electronic data capture software REDCap will ensure correctly inputted data and a total concealment of the assigned allocation prior to randomization. The status of recruitment will easily be followed in real-time through the web and motivate the surgical centers to continue to recruit. Another advantage of the online database will be the feasibility of monitoring the whole study.

Moreover, since umbilical hernias are very common in the outpatient clinical setting, we are confident in achieving the required number of participants. However, the time frame of the inclusion period may be at risk of extension due to the COVID-19 pandemic.

Finally, for ethical considerations, the benefit of what this trial can offer umbilical hemia patients outweighs the risks. The risks associated with using a small onlay mesh in this trial are considered to be of a low frequency and if so, without any severity. Due to the limited subcutaneous dissection required in the mesh group, the risk of postoperative complication of seroma is expected to be equal in both groups. Likewise, by using a composite half-absorbable microporous lightweight mesh, the risk of pain after surgery is expected to be equal in both groups. We believe the risk of recurrence can significantly be reduced by using a small onlay mesh compared to only suturing the defect. As such, this trial is expected to have a direct implication, both nationally and internationally, on the small umbilical hernia repair standards.

**Trial status**

This trial protocol Version 1.0 was published on Clinicaltrial.gov 31 January 2020 as approved by the Regional Ethics Review Board in Stockholm, Sweden (diary numbers; 2018/22-65 and 2019/05-608). Version 2.0 is referred to an addition of another surgical center (Sophiahemmet/GHP), approved by the Regional Ethics Review Board in Stockholm, Sweden at 24 February 2021. Recruitment started on 3 February 2020 and is estimated to be completed after 24 months. Currently, approximately 115 participants have been included and 85 are operated and randomized. Due to the COVID-19 pandemic, there is a risk that the inclusion period will need to be extended.

**Abbreviations**

BMI Body mass index

CT Computed tomography
COVID-19 Acronym for Coronavirus disease 2019, caused by the SARS-CoV-2 virus

REDCap Research electronic data capture

SSI Surgical site infection

VAS Visual Analogue Scale

VHPQ Ventral Hernia Pain Questionnaire

Declarations

Acknowledgements

We gratefully thank all the local site investigators, site staff and the head of the surgical department of each participating surgical center for their commitment to recruiting participants, for finding this trial interesting, and for contributing to very important research that may benefit hernia patients everywhere. We also thankfully acknowledge Sean Tuliprud for a great language review. Finally, a great acknowledge to Mats Ceder for the illustration of Figure 2.

Authors’ contributions {31b}

All authors adhere to the authorship guidelines of TRIALS and have agreed to this manuscript’s publication. MM is the lead principal investigator of the SUMMER Trial. MM conceived the study, lead on the protocol development and recruited the local site investigators at each of the participating surgical center. MM is the lead grant holder of a resident research grant by Karolinska Institutet and led the writing process to publish this protocol. BW and SB co-led the important process of evaluating the trial design and the protocol development. They greatly contributed to revisions of this manuscript to arrive at the final version for publication. SB is the lead grant holder of an research grant from Region Stockholm. BW led the development of the REDCap registration of the trial’s variables together with MM. GG led statistical protocol development and wrote parts of the manuscript’s statistical section.

Funding {4}

The trial has research funding from Region Stockholm and Region Stockholm with Karolinska Institutet in the form of a Medical Resident Research funding grant. The funding sources had no involvement in designing or conducting the trial. Neither will the funding sources have any involvement in the collection, analysis, or interpretation of the data, or writing of the trial's manuscripts (including this protocol). There is no commercial sponsoring.

Availability of data and materials {29}

All trial data will be uncoded and available at the closure, after statistical analysis, in Karolinska Institutet’s electronic notebook database and can be provided on request.
Ethics approval and consent to participate

Approval of the study protocol was obtained 12 December 2018 by the Regional Ethics Review Board in Stockholm, Sweden (diary number; 2018/22-65). Approval of the trial surgical centers before recruitment of participants from each surgical centra was obtained 31 January 2020 and 24 February 2021 (diary number; 2019/05-608 and 2021-00597). All procedures performed in the study involving human participants are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Participating investigators have the responsibility to give both oral and written information to patients about the trial. Signed informed consent from all participants will be obtained and maintained prior to inclusion in the trial. Any amendments to the study protocol will be submitted to the ethics review board prior to their implementation.

Consent for publication

Consent for publication of the uncoded data of the participants and the results of the trial will be obtained from all participants prior to study entry and will be disclosed in the written information about the trial provided to them.

Competing interests

The authors declare that they have no competing interests.

References

1. Register for Swedish Ventral Hernias. http://www.ventralhernia.se. Accessed 23 Oct 2020
2. Mayo WJ: VI. An Operation for the Radical Cure of Umbilical Hemia. Ann Surg 1901, 34(2):276-280.
3. Eryilmaz R, Sahin M, Tekelioglu MH: Which repair in umbilical hernia of adults: primary or mesh? Int Surg 2006, 91(5):258-261.
4. Sanjay P, Reid TD, Davies EL, Arumugam PJ, Woodward A: Retrospective comparison of mesh and sutured repair for adult umbilical hernias. Hernia 2005, 9(3):248-251.
5. Halm JA, Heisterkamp J, Veen HF, Weidema WF: Long-term follow-up after umbilical hernia repair: are there risk factors for recurrence after simple and mesh repair. Hernia 2005, 9(4):334-337.
6. Polat C, Dervisoglu A, Senyurek G, Bilgin M, Erzurumlu K, Ozkan K: Umbilical hernia repair with the prolene hernia system. Am J Surg 2005, 190(1):61-64.
7. Stabilini C, Stella M, Frascio M, De Salvo L, Fornaro R, Larghero G, Mandolfino F, Lazzara F, Gianetta E: Mesh versus direct suture for the repair of umbilical and epigastric hernias. Ten-year experience. Ann Ital Chir 2009, 80(3):183-187.
8. Ponten JE, Leenders BJ, Charbon JA, Nienhuijs SW: A consecutive series of 235 epigastric hernias. Hernia 2015, 19(5):821-825.
9. Tollens T, Den Hondt M, Devroe K, Terry C, Speybroeck S, Aelvoet C, Vanrykel JP: Retrospective analysis of umbilical, epigastric, and small incisional hernia repair using the Ventralex hernia patch. *Hernia* 2011, **15**(5):531-540.

10. Venclauskas L, Silanskaite J, Kiudelis M: Umbilical hernia: factors indicative of recurrence. *Medicina (Kaunas)* 2008, **44**(11):855-859.

11. Arroyo A, Garcia P, Perez F, Andreu J, Candela F, Calpena R: Randomized clinical trial comparing suture and mesh repair of umbilical hernia in adults. *Br J Surg* 2001, **88**(10):1321-1323.

12. Christoffersen MW, Helgstrand F, Rosenberg J, Kehlet H, Bisgaard T: Lower reoperation rate for recurrence after mesh versus sutured elective repair in small umbilical and epigastric hernias. A nationwide register study. *World J Surg* 2013, **37**(11):2548-2552.

13. Christoffersen MW, Helgstrand F, Rosenberg J, Kehlet H, Strandfelt P, Bisgaard T: Long-term recurrence and chronic pain after repair for small umbilical or epigastric hernias: a regional cohort study. *Am J Surg* 2015, **209**(4):725-732.

14. Kaufmann R, Halm JA, Eker HH, Klitsie PJ, Nieuwenhuizen J, van Geldere D, Simons MP, van der Harst E, van 't Riet M, van der Holt B et al: Mesh versus suture repair of umbilical hernia in adults: a randomised, double-blind, controlled, multicentre trial. *Lancet* 2018, **391**(10123):860-869.

15. Bisgaard T, Kaufmann R, Christoffersen MW, Strandfelt P, Gluud LL: Lower Risk of Recurrence After Mesh Repair Versus Non-Mesh Sutured Repair in Open Umbilical Hernia Repair: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Scand J Surg* 2019, **108**(3):187-193.

16. Kockerling F, Brunner W, Mayer F, Fortelny R, Adolf D, Niebuhr H, Lorenz R, Reinpold W, Zarras K, Weyhe D: Assessment of potential influencing factors on the outcome in small (< 2 cm) umbilical hernia repair: a registry-based multivariable analysis of 31,965 patients. *Hernia* 2020.

17. Aslani N, Brown CJ: Does mesh offer an advantage over tissue in the open repair of umbilical hernias? A systematic review and meta-analysis. *Hernia* 2010, **14**(5):455-462.

18. Nguyen MT, Berger RL, Hicks SC, Davila JA, Li LT, Kao LS, Liang MK: Comparison of outcomes of synthetic mesh vs suture repair of elective primary ventral herniorrhaphy: a systematic review and meta-analysis. *JAMA Surg* 2014, **149**(5):415-421.

19. Westen M, Christoffersen MW, Jorgensen LN, Stigaard T, Bisgaard T: Chronic complaints after simple sutured repair for umbilical or epigastric hernias may be related to recurrence. *Langenbecks Arch Surg* 2014, **399**(1):65-69.

20. Erritzoe-Jervild L, Christoffersen MW, Helgstrand F, Bisgaard T: Long-term complaints after elective repair for small umbilical or epigastric hernias. *Hernia* 2013, **17**(2):211-215.

21. Henriksen NA, Montgomery A, Kaufmann R, Berrevoet F, East B, Fischer J, Hope W, Klassen D, Lorenz R, Renard Y et al: Guidelines for treatment of umbilical and epigastric hernias from the European Hernia Society and Americas Hernia Society. *Br J Surg* 2020, **107**(3):171-190.

22. Muysoms FE, Miserez M, Berrevoet F, Campanelli G, Champault GG, Chelala E, Dietz UA, Eker HH, El Nakadi I, Hauters P et al: Classification of primary and incisional abdominal wall hernias. *Hernia* 2009, **13**(4):407-414.
23. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C et al: The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009, 250(2):187-196.

24. Clay L, Franneby U, Sandblom G, Gunnarsson U, Strigard K: Validation of a questionnaire for the assessment of pain following ventral hernia repair—the VHPQ. Langenbecks Arch Surg 2012, 397(8):1219-1224.

Table

**Table 1**
List of all inclusion and exclusion criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| · Elective surgery of a primary umbilical hernia with a defect ≤ 2 cm that has been measured clinically or with radiology | · Umbilical hernia with a defect > 2 cm measured clinically, with radiology or with a ruler intra-operatively |
| · Age > 18 years | · Multiple defects |
| · Patients with oral and written informed consent | · Incisional hernia: previous surgery in the area of the operation |
| | · Recurrent umbilical hernia |
| | · Epigastric hernia |
| | · Another operative procedure at the same time |
| | · Pregnancy |
| | · Infected wounds |
| | · Acute operation (incarcerated hernia) |
| | · BMI > 35 kg/m² |
| | · Ascites |
| | · Immunosuppression |
| | · Anticoagulant treatment |
| | · Connective tissue disorder |

BMI; Body Mass Index.

Figures
| TIMEPOINT | ENROLMENT | INTERVENTIONS | ASSESSMENT OF BASELINE VARIABLES | ASSESSMENT OF OUTCOME VARIABLES |
|-----------|-----------|---------------|---------------------------------|--------------------------------|
|           |           |               |                                 |                                |
|           | Enrolment | Surgery       | Post-allocation Follow-up | Close-out |
|           | t         | 0             | 30 days            | 1 year   | 3 year |
| 3 year    |           |               |                    |          |        |
| ENROLMENT |           |               |                                 |                                |
|           | Eligibility screen | X       | X                    | X        |        |
|           | Informed consent | X         | X                    | X        |        |
|           | Randomization | X           | X                    | X        |        |
|           | Allocation   | X           | X                    | X        |        |
| INTERVENTIONS | Suture repair | X         | X                    | X        |        |
|             | Onlay mesh repair | X       | X                    | X        |        |
| ASSESSMENT OF BASELINE VARIABLES | Demography | X         | X                    | X        |        |
|                                | Concomitant Comorbidities | X         | X                    | X        |        |
|                                | Description of Surgery     | X         | X                    | X        |        |
| ASSESSMENT OF OUTCOME VARIABLES | Complications              | X         | X                    | X        |        |
|                                | Pain - VAS                 | X         | X                    | X        |        |
|                                | Pain Questionnaire - VPHQ  | X         | X                    | X        |        |
|                                | Recurrence                 | X         | X                    | X        | X        |

Figure 1

Standards Protocol Items: Recommendations for Interventional Trials (SPIRIT). The SUMMER Trial.
Figure 2

a) dissection of the hernia sac b) a continuous suture repair c) a continuous suture repair with a 4x4 cm Onlay Ultrapro Advanced™ mesh on the closed defect, illustrating the 5 single sutures d) closure of the subumbilical surgical incision